This manuscript provides valuable high-resolution structural insights into the interaction between vaccine-elicited antibodies and SARS‑CoV‑2 evolution. The evidence is solid; however, the conclusions ...

Final OPTIMIZE‑1 outcomes were presented at ASCO GI 2026, with additional investigator‑initiated data accepted for AACR 2026. External portfolio progress: The first patient was dosed in Henlius’ Phase ...

This valuable study reports the architectural reorganization of the uterine luminal epithelium during the implantation period. The data presented are solid, although improvements are needed. This work ...

Gene syntax alters DNA supercoiling to amplify or suppress nearby genes. This could improve the effectiveness of gene ...

Who decides the names on the boxes on pharmacy shelves? And why does it cost more to buy the branded version than to get ...

Kiran Mazumdar of Biocon names her niece Claire as her successor, planning a gradual transition over five years. She remains ...

First Quarter ACV of $28 Million, Representing 12% Growth Continued Momentum in Transition to Hosted Software Licensing Schrödinger to Launch Bunsen, an Agentic AI Co-Scientist, This Summer Lilly’s ...

In a post on social network platform X, formerly Twitter, Shaw detailed out that Claire will eventually step into the role ...

Those pollen proteins become problems when the immune system develops an allergic antibody known as IgE to these proteins. When several IgE molecules bind to the allergen when it ...

Kiran Mazumdar-Shaw has identified her niece Claire Mazumdar as the future leader of Biocon, marking a major leadership ...

Kiran Mazumdar-Shaw , founder and chairperson of Biocon , has set in motion a clear succession plan as she prepares the ...

Claire Mazumdar, a 37-year-old biotechnology professional currently serves as founder and CEO of Bicara Therapeutics.